JP2001513982A5 - - Google Patents

Download PDF

Info

Publication number
JP2001513982A5
JP2001513982A5 JP2000507690A JP2000507690A JP2001513982A5 JP 2001513982 A5 JP2001513982 A5 JP 2001513982A5 JP 2000507690 A JP2000507690 A JP 2000507690A JP 2000507690 A JP2000507690 A JP 2000507690A JP 2001513982 A5 JP2001513982 A5 JP 2001513982A5
Authority
JP
Japan
Prior art keywords
polypeptide
nucleotide sequence
amino acid
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000507690A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001513982A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/017710 external-priority patent/WO1999010364A1/en
Publication of JP2001513982A publication Critical patent/JP2001513982A/ja
Publication of JP2001513982A5 publication Critical patent/JP2001513982A5/ja
Withdrawn legal-status Critical Current

Links

JP2000507690A 1997-08-29 1998-08-27 フォリスタチン−3 Withdrawn JP2001513982A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5624897P 1997-08-29 1997-08-29
US60/056,248 1997-08-29
PCT/US1998/017710 WO1999010364A1 (en) 1997-08-29 1998-08-27 Follistatin-3

Publications (2)

Publication Number Publication Date
JP2001513982A JP2001513982A (ja) 2001-09-11
JP2001513982A5 true JP2001513982A5 (enExample) 2006-01-05

Family

ID=22003166

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000507690A Withdrawn JP2001513982A (ja) 1997-08-29 1998-08-27 フォリスタチン−3

Country Status (6)

Country Link
US (3) US6372454B2 (enExample)
EP (1) EP1015468A4 (enExample)
JP (1) JP2001513982A (enExample)
AU (1) AU8921698A (enExample)
CA (1) CA2302525A1 (enExample)
WO (1) WO1999010364A1 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
WO1999010364A1 (en) 1997-08-29 1999-03-04 Human Genome Sciences, Inc. Follistatin-3
US5942420A (en) 1997-11-17 1999-08-24 Millennium Biotherapeutics, Inc. Molecules of the follistatin-related protein family and uses therefor
US6797271B2 (en) * 1999-03-25 2004-09-28 Genesis Research & Development Corporation Limited Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides
US7083791B2 (en) 1999-03-25 2006-08-01 Genesis Research & Development Corporation Limited Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides
WO2002038175A1 (en) * 2000-11-07 2002-05-16 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
WO2002080952A2 (en) * 2001-04-09 2002-10-17 Lorantis Limited Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
AUPR638101A0 (en) * 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
GB2385052A (en) * 2002-02-05 2003-08-13 Leuven K U Res & Dev Treatment of spondyloarthropathies
EP1572934A4 (en) * 2002-02-21 2007-12-19 Wyeth Corp FOLLISTATIN DOMAIN CONTAINING PROTEINS
AU2003217612A1 (en) * 2002-02-21 2003-09-09 Wyeth GASP1: a follistatin domain containing protein
AU2003211375A1 (en) * 2002-02-27 2003-09-09 Science Park Corporation Computer file system driver control method, program thereof, and program recording medium
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
CA2510715A1 (en) 2002-12-20 2004-07-08 Enkam Pharmaceuticals A/S Method of modulation of interaction between receptor and ligand
AU2003901267A0 (en) * 2003-03-19 2003-04-03 Monash University Assessment method
KR20060026860A (ko) 2003-06-02 2006-03-24 와이어쓰 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (gdf8) 저해제의 용도
EP1677816B1 (en) * 2003-10-06 2014-03-12 Paranta Biosciences Limited Follistatin for use in down-regulation an inflammatory response
EP3059245B1 (en) * 2004-07-23 2018-11-07 Acceleron Pharma Inc. Actrii receptor antagonistic antibodies
US20060257935A1 (en) * 2005-04-26 2006-11-16 Ajinomoto Co., Inc. Hematopoietic factor production promoter
SI1915397T1 (sl) 2005-08-19 2015-05-29 Wyeth Llc Antagonistična protitelesa proti GDF-8 in uporabe pri zdravljenju ALS in drugih obolenj, povezanih z GDF-8
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
MX2008006626A (es) 2005-11-23 2008-09-24 Acceleron Pharma Inc Antagonistas de activin-actriia y usos para promover el crecimiento de huesos.
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US20070275036A1 (en) 2006-05-18 2007-11-29 Celldyne Biopharma, Llc Avian follistatin product
US10835576B2 (en) 2006-05-18 2020-11-17 Myos Rens Technology Inc. Method of obtaining effective amounts of avian follistatin
EP2097095B1 (en) 2006-11-29 2016-01-27 Nationwide Children's Hospital Myostatin inhibition for enhancing muscle and/or improving muscle function
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2008094708A2 (en) * 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI782836B (zh) * 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TWI606062B (zh) 2007-02-09 2017-11-21 艾瑟勒朗法瑪公司 包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途
US20100279409A1 (en) * 2007-09-13 2010-11-04 Neil Robson Method for modifying celluar immune resonse by modulating activin activity
WO2009038745A1 (en) * 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
JP5731198B2 (ja) * 2007-09-27 2015-06-10 イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
AU2009253780B2 (en) * 2008-06-05 2014-08-14 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
CA2729096C (en) 2008-06-26 2020-04-28 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
KR20190049912A (ko) 2008-06-26 2019-05-09 악셀레론 파마 인코포레이티드 액티빈-actriia의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HRP20191109T1 (hr) 2008-08-14 2019-09-20 Acceleron Pharma Inc. Gdf klopke za uporabu u liječenju anemije
WO2010083034A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
ES2869580T3 (es) 2009-09-09 2021-10-25 Acceleron Pharma Inc Antagonistas de ActRIIB y dosificación y usos de los mismos para tratar obesidad o diabetes tipo 2 regulando el contenido de grasa corporal
EP3260130B1 (en) * 2009-11-03 2021-03-10 Acceleron Pharma Inc. Methods for treating fatty liver disease
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
DK2402288T3 (en) 2010-07-02 2017-02-06 Alfa Laval Corp Ab GAS SCRUBBER FLUID CLEANING EQUIPMENT
JP2014502260A (ja) 2010-11-08 2014-01-30 アクセルロン ファーマ, インコーポレイテッド Actriia結合剤およびその使用
CN103492016A (zh) 2010-11-23 2014-01-01 普莱萨格生命科学公司 用于实体递送的治疗方法和组合物
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
GR1007832B (el) * 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
CA2867202A1 (en) * 2012-05-17 2013-11-21 Paranta Biosciences Limited A method of treatment and agents useful for same
KR101704893B1 (ko) 2012-06-15 2017-02-08 화이자 인코포레이티드 Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
IL290653B2 (en) 2012-10-24 2025-05-01 Celgene Corp Biomarker for use in the treatment of anemia
ES2884095T3 (es) 2012-11-02 2021-12-10 Celgene Corp Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos
US20150361163A1 (en) 2014-04-18 2015-12-17 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
CN104161959A (zh) * 2014-08-25 2014-11-26 山西藏象康寿科技有限公司 一种预防或治疗女性乳房不适症状的药食同源植物提取物制剂及制备方法
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
AU2015358469B2 (en) 2014-12-03 2021-05-27 Acceleron Pharma Inc. Activin-ActRII antagonists and uses for treating anemia
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
JP2016131541A (ja) * 2015-01-20 2016-07-25 学校法人藤田学園 トランスジェニック非ヒト哺乳動物及びその用途
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
EP3828199B1 (en) 2015-04-06 2025-10-15 Acceleron Pharma Inc. Alk7: actriib heteromultimers and uses thereof
WO2017079591A2 (en) 2015-11-04 2017-05-11 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
AU2016359695A1 (en) 2015-11-23 2018-06-14 Acceleron Pharma Inc. Methods for treating eye disorders
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
HUE054228T2 (hu) 2016-07-15 2021-08-30 Acceleron Pharma Inc Használható actriia polipeptideket tartalmazó összetételek a pulmonalis hypertónia kezelésében történõ alkalmazásra
PL3490582T3 (pl) 2016-07-27 2024-09-23 Acceleron Pharma Inc. Kompozycje do zastosowania w leczeniu mielofibrozy
EP3522934A4 (en) 2016-10-05 2020-04-15 Acceleron Pharma Inc. COMPOSITIONS AND METHODS FOR TREATING KIDNEY DISEASES
JP2023507794A (ja) 2019-12-20 2023-02-27 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 筋肉疾患の筋肉を標的とするための最適化された遺伝子療法
AU2024256934A1 (en) 2023-04-18 2025-11-06 Research Institute At Nationwide Children's Hospital, Inc. Gene therapy for treating limb girdle muscular dystrophy r9 and congenital muscular dystrophy 1c
WO2025188993A2 (en) 2024-03-07 2025-09-12 Research Institute At Nationwide Children's Hospital Gene therapy for treating gne-related disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999010364A1 (en) 1997-08-29 1999-03-04 Human Genome Sciences, Inc. Follistatin-3
US5942420A (en) 1997-11-17 1999-08-24 Millennium Biotherapeutics, Inc. Molecules of the follistatin-related protein family and uses therefor
JPH11225771A (ja) 1997-12-12 1999-08-24 Taisho Pharmaceut Co Ltd 細胞死抑制因子
AU758074B2 (en) 1998-04-29 2003-03-13 Genesis Research And Development Corporation Limited Polynucleotides isolated from skin cells and methods for their use
AU6098300A (en) 1999-07-16 2001-02-05 Human Genome Sciences, Inc. Follistatin-3

Similar Documents

Publication Publication Date Title
JP2001513982A5 (enExample)
JP2002516103A5 (enExample)
KR100891509B1 (ko) 연결체들
CA2309783A1 (en) Fibroblast growth factor-19
JP2003532365A5 (enExample)
CA2343655A1 (en) Interleukin 17-like receptor protein
JP2002502589A5 (enExample)
JP2002522041A5 (enExample)
JP2012152218A5 (enExample)
JP2002521055A5 (enExample)
JP2002518010A5 (enExample)
JP2006068016A5 (enExample)
JP2006223304A5 (enExample)
CA2338186A1 (en) Tumor necrosis factor-gamma
CA2378519A1 (en) Human cytokine receptor
IL145676A (en) Tumor necrosis factor homologs and nucleic acids encoding the same
CA2188279A1 (en) Interleukin-15 receptors
JP2003527078A5 (enExample)
JP2004041218A5 (enExample)
JP2005518212A5 (enExample)
CN105073977A (zh) 重组酵母转化体和用其制备免疫球蛋白Fc片段的方法
CN111004317B (zh) 一种犬重组干扰素α7及其制备方法与应用
CA2439452A1 (en) High-affinity antagonists of elr-cxc chemokines
JP3751883B2 (ja) ヒトインターフェロンアルファの発現分泌ベクターおよびそれを用いたヒトインターフェロンアルファの生産方法
JP2002504333A5 (enExample)